Table 3.

Effect of treatment on BOLD signal

Description	Cluster center	BOLD averaged amplitude signal (%)		P	qCBF		P	BOLD qCBF interaction
	x,y,z (mm)				(ml/100g/min)
		Statin Treated Subjects (n=8) (Mean ± SE)	Placebo Treated Subjects (n=7) (Mean ± SE)	statin vs. Placebo*(P)	Statin Treated Subjects (n=8) (Mean ± SE)	Placebo Treated Subjects (n=7) (Mean ± SE)	statin vs. Placebo*(P)	statin vs. Placebo **
Right angular gyrus	46,−54,40	0.265 ± 0.1	−0.19 ± 0.06	0.005	74.6 ± 10.4	54.3 ± 10.4	0.30	P = 0.824
Right middle temporal gyrus	66, −32, −26	0.30 ± 0.06	−0.21 ± 0.10	0.005	53.6 ± 8.6	44.8 ± 6.7	0.16	P = 0.354
Left superior parietal lobule	−18, −70,46	0.45 ± 0.16	−0.19 ± 0.10	0.010	70.2 ± 10.8	55.0 ± 13.1	0.44	P = 0.202
Right superior frontal sulcus	20, −20,58	0.40 ± 0.12	−0.05 ± 0.04	0.014	45.6 ± 8.0	33.9 ± 6.3	0.30	P = 0.75
Global Grey Matter					62.0 ± 16.8	60.0 ± 10.7	0.875	N/A
Global white Matter					46.9 ± 11.8	45.4 ± 7.7	0.713	N/A
		BOLD latency to PV faces (s)			Cerebral Blood Mean Transit Time (s)
Right middle frontal gyrus	30, −4,68	−0.40 ± 0.33	1.05 ± 0.12	0.008	5.68 ± 0.33	5.14 ± 0.19	0.29	N/A
Left precentral gyrus	−45, −5,24	−0.25 ± 0.16	1.02 ± 0.17	0.001	6.23 ± 0.39	6.22 ± 0.33	0. 73	N/A
Right posterior middle frontal gyrus	30, −7,43	−0.69 ± 0.12	0.65 ± 0.09	0.001	6.14 ± 0.40	6.09 ± 0.32	0.73	N/A
Left cuneus	−21, −62,18	−0.36 ± 0.21	0.87 ± 0.16	0.001	6.65 ± 0.39	6.35 ± 0.33	0.64	N/A

^*Group difference in BOLD and ASL between groups were tested by non-parametric Wilcoxon rank test.

^**Interactions of BOLD and ASL were tested by non-parametric Check Assumption of Parallelism (Sen, Adichie).